BioSpace News Archive

NeuroSense Therapeutics, a biotechnology company developing treatments for neurodegenerative diseases such as Amyotrophic Lateral Sclerosis (ALS), based on a novel combination drug therapy aiming at slowing or halting the disease progression, announces the successful completion of its first Phase IIa study.

Wugen Inc., a biotechnology company developing novel, universal allogeneic cell therapy platforms, today announced that it has entered into an exclusive license agreement with US-based HCW Biologics Inc. (HCW) for the use of their proprietary fusion molecules to manufacture Wugen’s cellular therapeutics for the treatment of cancer.

98point6, the on-demand digital primary care service that delivers personalized diagnosis, treatment and consultation to patients across the country, today announced a collaboration with Quest Diagnostics (

Varian announced that Chief Executive Officer Dow Wilson, after more than 16 years with the Company, will retire upon the successful completion of the proposed combination of Varian and Siemens Healthineers AG.

PierianDx, the global leader in clinical genomics knowledge, today announced the appointment of Lindsay Mateo as Chief Business Officer, effective immediately

Sengenics, the Functional Proteomics Company, today announced the commercial launch of the Sengenics AxCESS research services suite which features three new KREX-based functional protein arrays developed for higher throughput and cost-effective immuno-proteomics applications.

ObvioHealth, a global virtual research organization or VRO, today announced the launch of a hybrid clinical trial for the treatment of COVID-19, using an innovative study design with digital data capture to remotely monitor patient vitals.

White Oak Healthcare Finance, LLC (“White Oak”) today announced it acted as sole lender and administrative agent of a senior credit facility to support the acquisition of Parnell Pharmaceuticals Holdings, Ltd. (“Parnell”) by DW Healthcare Partners (“DWHP”)

BioCorRx Inc. (OTCQB: BICX) (the “Company”), a developer and provider of advanced solutions in the treatment of substance use disorders, today announced that the Company completed a private placement, whereby it issued 1.125 million common stock shares at a price of $2.00 per share, for total proceeds of $2.25 million.

Vibrent Health, a health technology company powering the future of precision health research, has created a participant advisory board made up of health experts who will advise Vibrent’s Participant Technology Systems Center (PTSC).